Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease

Muir, Andrew J., Levy, Cynthia, Janssen, Harry L.A., Montano‐Loza, Aldo J., Shiffman, Mitchell L., Caldwell, Stephen, Luketic, Velimir, Ding, Dora, Jia, Catherine, McColgan, Bryan J., McHutchison, John G., Mani Subramanian, G., Myers, Robert P., Manns, Michael, Chapman, Roger, Afdhal, Nezam H., Goodman, Zachary, Eksteen, Bertus, Bowlus, Christopher L., for the GS‐US‐321‐0102 Investigators·2019·Hepatology

DOI 10.1002/hep.30237

Cited by (196)

Items 101–196 of 196

Primary sclerosing cholangitis
Erik von Seth, Tom H. Karlsen, Atsushi Tanaka, Cyriel Y. Ponsioen, Annika M Bergquist · 2026 · The Lancet
Recent advances in the treatment of primary sclerosing cholangitis
Einar Stefan Bjornsson, Evangelos Kalaitzakis · 2020 · Expert Review of Gastroenterology & Hepatology
Automated image analysis of keratin 7 staining can predict disease outcome in primary sclerosing cholangitis
Nelli Sjöblom, Sonja Boyd, Anniina Manninen, Sami Blom, Anna Knuuttila, Martti A. Färkkilä, Johanna Arola · 2022 · Hepatology Research
Anti-integrin αvβ6 Autoantibodies Are Increased in Primary Sclerosing Cholangitis Patients With Concomitant Inflammatory Bowel Disease and Correlate With Liver Disease Severity
Hannah Bloemen, Alexandra E. Livanos, Adrielly Martins, Richard Dean, Ana Catarina Bravo, Arno R. Bourgonje, Michael Tankelevich, Jake T. Herb, Judy H. Cho, André Anastácio Santos et al. · 2024 · Clinical Gastroenterology and Hepatology
Medical treatment of primary sclerosing cholangitis: What have we learned and where are we going?
Tom H. Karlsen, Kristin Kaasen Jørgensen, Annika M Bergquist · 2024 · Hepatology
Lysyl oxidase inhibitors in colorectal cancer progression
Liu, Muxian, Wang, Jie, Liu, Meihong · 2025 · Translational Oncology
Fibrosis in Mesothelioma: Potential Role of Lysyl Oxidases
Lara Perryman, Steven G. Gray · 2022 · Cancers
p70 Ribosomal Protein S6 Kinase Is a Checkpoint of Human Hepatic Stellate Cell Activation and Liver Fibrosis in Mice
Florian Paul Reiter, Liangtao Ye, Andrea Ofner, Tobias S. Schiergens, Andreas Ziesch, Lydia Brandl, Najib Ben Khaled, Simon D. Hohenester, Ralf Wimmer, Renate Artmann et al. · 2021 · Cellular and Molecular Gastroenterology and Hepatology
AI-based histologic scoring enables automated and reproducible assessment of enrollment criteria and endpoints in NASH clinical trials
Janani S. Iyer, Harsha Pokkalla, Charles Biddle-Snead, Oscar M. Carrasco‐Zevallos, Mary Lin, Zahil Shanis, Quang Le, Dinkar Juyal, Maryam Pouryahya, Aryan Pedawi et al. · 2023 · medRxiv
Analytical performance of the Enhanced Liver Fibrosis (ELF) Test on the Atellica IM Analyzer
Agostino Palladino, Matthew F. W. Gee, Victoria Shalhoub, David Kiaei · 2023 · Clinica Chimica Acta
An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents
Vinka Rupčić Rubin, Kristina Bojanić, Martina Smolić, Jurica Rubin, Ashraf Abdou Tabll, Robert Smolić · 2021 · Journal of Clinical and Translational Hepatology
Crosstalk of lysyl oxidase-like 1 and lysyl oxidase prolongs their half-lives and regulates liver fibrosis through Notch signal
Ning Zhang, Aiting Yang, Wen Zhang, Hong Li, Anjian Xu, Xuzhen Yan, Qi Han, Bingqiong Wang, Hong You, Wei Chen · 2024 · Hepatology Communications
Machine Learning Identifies Key Proteins in Primary Sclerosing Cholangitis Progression and Links High CCL24 to Cirrhosis
Tom Snir, Raanan Greenman, Revital Aricha, Matthew B. Frankel, John Lawler, Francesca Saffioti, Massimo Pinzani, Douglas Thorburn, Adi Mor, Ilan Vaknin · 2024 · International Journal of Molecular Sciences
Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis
Douglas Thorburn, Diana Julie Leeming, William Barchuk, Ya Wang, Xiaomin Lu, Vladislav A. Malkov, Kaori L. Ito, Christopher L. Bowlus, Cynthia Levy, Zachary D Goodman et al. · 2024 · Hepatology Communications
Management of primary sclerosing cholangitis: Current state-of-the-art
Guilherme Grossi Lopes Cançado, Gideon Morris Hirschfield · 2024 · Hepatology Communications
Current Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases
Marilena Durazzo, Arianna Ferro, Victor Navarro‐Tableros, Andrea Gaido, Paolo Fornengo, Fiorella Altruda, Renato Romagnoli, Søren K. Moestrup, Pier Luigi Calvo, Sharmila Fagoonee · 2025 · Biomolecules
From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension
Michał Porada, Łukasz Bułdak · 2025 · Metabolites
Lysine Deacetylation Is a Key Function of the Lysyl Oxidase Family of Proteins in Cancer
Xingxing Wu, Xue Li, Luwei Wang, Xianxia Bi, Weihong Zhong, Jicheng Yue, Yue Eugene Chin · 2024 · Cancer Research
Precision medicine in primary sclerosing cholangitis
James B. Maurice, Douglas Thorburn · 2019 · Journal of Digestive Diseases
Reprint of “The complex dynamics of myocardial interstitial fibrosis in heart failure. Focus on collagen cross-linking”
Arantxa González, Begoña López, Susana Ravassa, Gorka San José, Javier Dı́ez · 2019 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Spatial transcriptomic validation of a biomimetic model of fibrosis enables re-evaluation of a therapeutic antibody targeting LOXL2
Joseph A. Bell, Elizabeth R. Davies, Christopher J. Brereton, Milica Vukmirovic, James Roberts, Kerry Lunn, Leanne Wickens, Franco Conforti, Robert A. Ridley, Jessica Ceccato et al. · 2024 · Cell Reports Medicine
Role of Lysyl Oxidase-Like Protein 3 in the Pathogenesis of Graves’ Orbitopathy in Orbital Fibroblasts
Seung Hyun Park, Soo Hyun Choi, Hyun Young Park, JaeSang Ko, Jin Sook Yoon · 2024 · Investigative Ophthalmology & Visual Science
Mesenchymal stem cell-derived extracellular vesicles attenuate periductal fibrosis by inhibiting Th17 differentiation in human liver multilineage organoids and Mdr2−/− mice
Wenyi Chen, Xinyi Chen, Feiqiong Gao, Qigu Yao, Sheng Cheng, Qiaoling Pan, Jiong Yu, Jinfeng Yang, Guanghua Ma, Jintao Gong et al. · 2025 · Journal of Nanobiotechnology
Innovative Nanotechnological Formulations to Reach the Hepatic Stellate Cell
Klaas Poelstra · 2020 · Current Tissue Microenvironment Reports
Future Medical Treatment of PSC
Elisabeth Krones, Hanns–Ulrich Marschall, Peter Fickert · 2019 · Current Hepatology Reports
SPECT Imaging of Lysyl Oxidase-like 2 in a Model of Idiopathic Pulmonary Fibrosis
Romane Vizier, Anaïs-Rachel Garnier, Alexandre M.M. Dias, Mathieu Moreau, Michaël Claron, Bertrand Collin, Franck Denat, Pierre‐Simon Bellaye, Victor Gonçalves · 2023 · Molecular Pharmaceutics
The Oral Cholate Challenge Test Quantifies Risk for Liver-Related Clinical Outcomes in Primary Sclerosing Cholangitis
Steve M. Helmke, John Kittelson, Joanne C. Imperial, Michael P. McRae, Gregory T. Everson · 2024 · Gastro Hep Advances
Pharmacologic management of primary sclerosing cholangitis: what’s in the pipeline?
Jaspreet S. Suri, Vilas R. Patwardhan, Alan Bonder · 2019 · Expert Review of Gastroenterology & Hepatology
Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis
Amandeep K. Dhillon, Andreas Emanuel Kremer, Martin Kummen, Kirsten Muri Boberg, Ronald P.J. Oude Elferink, Tom H. Karlsen, Ulrich H. Beuers, Mette Nåmdal Vesterhus, Johannes R. Hov · 2019 · Scientific Reports
Noninvasive prognostic models, imaging, and elastography to predict clinical events in primary sclerosing cholangitis: A review
Mark W. Russo · 2023 · World Journal of Hepatology
Hepatic Fibrosis and Liver Cancer
Aina Anton, Scott L. Friedman, Bruno Cogliati · 2025 · Seminars in Liver Disease
Biliary fibrosis is an important but neglected pathological feature in hepatobiliary disorders: from molecular mechanisms to clinical implications
Jinyu Zhao, Ping Yue, Ningning Mi, Matu Li, Wenkang Fu, Xianzhuo Zhang, Long Gao, Mingzhen Bai, Liang Tian, Ningzu Jiang et al. · 2024 · Medical Review
Long Term Effect of Simvastatin in Primary Sclerosing Cholangitits: A Placebo-Controlled, Double-Blind, Multicenter Phase III Study (Piscatin)
2022 · British Journal of Gastroenterology
An overview of recent treatment options for primary sclerosing cholangitis
Ioanna Mousavere · 2023 · Annals of Gastroenterology
Copper chelation reduces early collagen deposition and preserves saliva secretion in irradiated salivary glands
Kihoon Nam, Harim Tavares dos Santos, Frank Maslow, Travis Small, Vinit Shanbhag, Michael J. Petris, Olga J. Baker · 2024 · Heliyon
Mechanisms of Fibroblast Activation during Fibrotic Tissue Remodeling
Aleix Rius Rigau, Clara Dees · 2024 · Fibrosis
Impact of heterogeneity in liver matrix and intrahepatic cells on the progression of hepatic fibrosis
Zhongtao Sun, Guobao Chen · 2024 · Tissue and Cell
Targets in the Tumour Matrisome to Promote Cancer Therapy Response
Siti Munira Abd Jalil, Jack C. Henry, Angus J.M. Cameron · 2024 · Cancers
An update on novel pharmacological agents for primary sclerosing cholangitis
Camilla Gallo, Bright Oworae Howardson, Laura Cristoferi, Marco Carbone, M. Eric Gershwin, Pietro Invernizzi · 2022 · Expert Opinion on Therapeutic Targets
PSC-specific prognostic scores associated with graft loss and overall mortality in recurrent PSC after liver transplantation
Ellina Lytvyak, Dennis Wang, Devika Shreekumar, Maryam Ebadi, Yousef Alrifae, Andrew L. Mason, Aldo J. Montaño‐Loza · 2025 · Digestive and Liver Disease
Impact of mechanical property alterations on cancer cell motility and metastasis
Polina Belousova, Sangwoo Kwon, Min‐Hyung Jung, Kyung Sook Kim · 2026 · Critical Reviews in Oncology/Hematology
Oral Vancomycin Is Not Associated With Meaningful Changes in Liver-Related End Points Among Adults With Primary Sclerosing Cholangitis: A Randomized, Placebo-Controlled Trial
John E. Eaton, Mitchell W. Clayton, Denise M. Harnois, Duke J. Butterfield, Nan Zhang, Sudhakar Kundapur Venkatesh, Nicholas V. Nguyen, Andrea A. Gossard, Lindor Kd, Nicholas F. LaRusso et al. · 2026 · The American Journal of Gastroenterology
Selective inhibition of hepatic stellate cell and fibroblast-derived LOXL1 attenuates BDL- and Mdr2 −/− -induced cholestatic liver fibrosis
Xuzhen Yan, Ning Zhang, Luyang Wei, Wen Zhang, Tao Huang, Weiyu Li, Wei Chen, Aiting Yang, Hong You · 2023 · American Journal of Physiology-Gastrointestinal and Liver Physiology
Nebokitug, an Anti-chemokine (C-C Motif) Ligand 24 Monoclonal Antibody, in Patients With Primary Sclerosing Cholangitis: A Phase 2 Study
Christopher L. Bowlus, Douglas Thorburn, Stephen T. Barclay, Deepak Joshi, María‐Carlota Londoño, Parvez Mantry, Rifaat Safadi, Revital Aricha, Chris Cirillo, Matthew B. Frankel et al. · 2025 · The American Journal of Gastroenterology
Bile acids as therapeutic agents
Brandon Vu, Ryo Kawamoto, Priscila Villalba‐Davila, Xinzhong Dong, Wikrom W. Karnsakul · 2026 · Frontiers in Pharmacology
Novel Therapies for Managing Cholestasis
Priscila Santiago, Cynthia Levy · 2020 · Clinical Liver Disease
Treatment of Primary Sclerosing Cholangitis Including Transplantation
William H. Wheless, Mark W. Russo · 2023 · Clinics in Liver Disease
Redox Potentials of Disulfide Bonds in LOXL2 Studied by Nonequilibrium Alchemical Simulation
Lirui Lin, Haiying Zou, Wenjin Li, Li‐Yan Xu, En‐Min Li, Geng Dong · 2021 · Frontiers in Chemistry
Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective
Giuseppe Losurdo, Antonietta Gerarda Gravina, Luca Maroni, Enrico Maria Gabrieletto, Gianluca Ianiro, Alberto Ferrarese, Alessia Visintin, Leonardo Frazzoni, Gaia Pellegatta, Anna Sessa et al. · 2021 · Digestive and Liver Disease
Spanish clinical practice guidelines for the diagnosis and management of cholestatic liver diseases in adult and pediatric population: Joint report from AEEH and SEGHNP
Álvaro Díaz‐González, Cristina Molera, Elena Gómez Domínguez, Gema Muñoz‐Bartolo, Javier Ampuero, Conrado Fernández‐Rodríguez, Jesús Quintero, Esther Molina, Magdalena Salcedo, Antonio Olveira et al. · 2025 · Gastroenterología y Hepatología (English Edition)
A novel cell-permeable LOXL2 inhibitor PAT-1251 potently suppresses biliary liver fibrosis via collagen crosslinking-dependent and -independent mechanisms
Ping An, Guangyan Wei, Pinzhu Huang, Heansika Matta, Wenda Li, Yi Lin, Jing Wang, Bain Gretchen, Yury V. Popov · 2025 · Hepatology Communications
LOXL2 in non‐alcoholic Steatohepatitis ( NASH ): Insights into fibrosis pathogenesis and therapeutic potential
Joys Rachel Immanuel, Rajnish Kumar, Ashish Kumar Agrahari, Shailendra Asthana · 2024 · Liver international communications.
Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitis
Nasir Hussain, Christopher Ma, Gideon Morris Hirschfield, Martine Walmsley, Paula Hanford, Mette Nåmdal Vesterhus, Kris V. Kowdley, Annika M Bergquist, Cyriel Y. Ponsioen, Cynthia Levy et al. · 2024 · BMJ Open
LOXL-2 and TNC-C Are Markers of Liver Fibrogenesis in HCV/HIV-, HIV- and HCV-Infected Patients
Akif Altınbaş, Jacinta Alison Holmes, Shadi Salloum, Anna Lidofsky, Nadia Alatrakchi, Ma Somsouk, Peter W. Hunt, Steven G. Deeks, Kara W Chew, Georg M. Lauer et al. · 2022 · Biomarkers in Medicine
Great Expectations: Can Magnetic Resonance Elastography Accelerate Progress in Primary Sclerosing Cholangitis Research?
Mustafa Rifaat Bashir, Andrew Joseph Muir · 2019 · Clinical Gastroenterology and Hepatology
Derivation and validation of Transform equations to convert historical Enhanced liver fibrosis (ELF) scores to modern equivalents
Matthew F. W. Gee, Agostino Palladino, H. Roma Levy, Edward Bentz Devol, David Kiaei · 2023 · Clinica Chimica Acta
Cholangiocyte biology in primary sclerosing cholangitis and other cholangiopathies: pathogenesis, clinical insights, and experimental tools
Nidhi Jalan‐Sakrikar, Abid A. Anwar, Ahmad Ali, Navine Nasser‐Ghodsi, Antonia Felzen, Robert C. Huebert, Nicholas F. LaRusso, Steven P. O’Hara · 2026 · Physiological Reviews
Prognostic modeling in biliary diseases
Camelia Ciobanu, Mark W. Russo · 2023 · Current Opinion in Gastroenterology
Novel preclinical developments of the primary sclerosing cholangitis treatment landscape
Aalam Sohal, Kris V. Kowdley · 2024 · Expert Opinion on Investigational Drugs
Pathophysiologic Basis for Alternative Therapies for Cholestasis
Claudia Daniela Fuchs, Emina Halilbasic, Michael A Trauner · 2020 · Wiley eBooks
Liver sinusoidal cells in the diagnosis and treatment of liver diseases: Role of hepatic stellate cells
Elisabetta Caon, Roberta Forlano, Benjamin Harvey Mullish, Pinelopi Manousou, Krista Rombouts · 2024 · Elsevier eBooks
Primary sclerosing cholangitis and IgG4-associated cholangitis
Christopher L. Bowlus · 2024 · Elsevier eBooks
Spatial heterogeneity in liver stiffness does not predict clinical outcomes in patients with primary sclerosing cholangitis
Erick Cruz Grave, Connie Chan, Michael T. Corwin, Richard D. Dean, Sandeep Dhaliwal, Maryam Yazdanfar, Christopher L. Bowlus · 2025 · Hepatology Communications
Targeting X-box–binding protein-1 by Decoy oligodeoxynucleotide modulates fibrogenic features of activated hepatic stellate cells
Roya Solhi, Majid Lotfinia, Zahra Abdi, Abbas Sahebghadam Lotfi, Andreas Klaus Nussler, Ali Zarrabi, Massoud Vosough · 2025 · Journal of Pharmacology and Experimental Therapeutics
Primary Sclerosing Cholangitis
Nasir Hussain, Palak Jitendrakumar Trivedi · 2026 · Clinics in Liver Disease
The Matrix Reloaded: The Hepatic Matrisome as a Therapeutic Opportunity to Fight Liver Fibrosis
Cristina Benavides Tutillo, Pepa Kecheva, Fernando Solano, Olga Martínez-Arroyo, Esplugues Jv, Ana Blas‐García, Nadezda Apostolova · 2026 · Biomolecules
[Apolipoprotein B and small, dense LDL-C].
Yasuki Ito · 2012 · PubMed
LOC102553417 silencing facilitates the apoptosis of hepatic stellate cells via the miR‑30e/MTDH axis
Wujun Wei, Cheng Lin, Rentong Hu, Jingjing Huang, Xiaohao Chen, Lv Zhou, Jiazhu Wei, Yibin Deng, Chunfang Wang · 2022 · Molecular Medicine Reports
Navigating the liver landscape: upcoming pharmacotherapies for primary sclerosing cholangitis
Hoang Nam Pham, Linh Pham, Keisaku Sato · 2024 · Expert Opinion on Pharmacotherapy
Primary sclerosing cholangitis
Jawad Ahmad, Priya Grewal · 2024 · Elsevier eBooks
Abundant Expression of Lysyl Oxidase‐like 2 Protein in Intrahepatic Bile Ducts of Infants With Biliary Atresia
Stefany Honigbaum, Qingfeng Zhu, Andrew J. Layman, Robert A. Anders, Kathleen B. Schwarz · 2019 · Journal of Pediatric Gastroenterology and Nutrition
Inhibition of LOXL2 and Other Lysyl Oxidase (Like) Enzymes: Intervention at the Core of Fibrotic Pathology
Alison D. Findlay, Craig I. Turner, Dieter W. Hamprecht · 2020 · Royal Society of Chemistry eBooks
Sclerosing Cholangitis in Children
William F. Balistreri, Simon Lam · 2021 · Cambridge University Press eBooks
Anti-fibrotic Therapy for Chronic Liver Diseases Review
Maged Naser, Mohamed M. Naser, Lamia H. Shehata · 2021 · International Journal of Progressive Sciences and Technologies
Biological therapies in patients with liver disease: are they really lifesavers?
Giovanni Vitale, Stefano Gitto, Claudia Campani, Laura Turco, Anna Baldan, Fabio Marra, Maria Cristina Morelli · 2021 · Expert Opinion on Biological Therapy
Significance of nuclear upregulation of LOXL2 in fibroblasts and myofibroblasts in the fibrotic process of acute respiratory distress syndrome
Ayako Matsuo, Shigehisa Yanagi, Hironobu Tsubouchi, Ayako Miura, Takafumi Shigekusa, Nobuhiro Matsumoto, Masamitsu Nakazato · 2020
Integration of Bidirectional Long Short-Term Memory (Bilstm) and Two-Dimensional Convolutional Neural Networks (CONV2D) for Improved Hepatitis A and B Prediction
Oyinlola Dupe Sharon · 2024 · International Journal of Research Publication and Reviews
Lysyl Oxidase-like 2 Dysregulation Increases the Risk of Post- Operative Fibrotic Scars Formation in the Female Reproductive Tract: A Novel Therapeutic Target to Reduce Fibrogenesis
Rozita Khodashahi, Shirin Madadkar Dehkordi‌, Amir Mahmoud Ahmadzade, Gordon A. Ferns, Mohsen Aliakbarian, Mohammad‐Hassan Arjmand · 2024 · Current Medicinal Chemistry
Current basic and preclinical research for treatment of radiation therapy–induced hyposalivation
Olga J. Baker, Harim Tavares dos Santos, Kihoon Nam · 2025 · JADA Foundational Science
Genes that cause severe liver disease in children also influence risk and severity of common liver conditions in adults
Joanne Mushi, Preeti Sharma, Annabelle Schofield, Vincent Lingzhi Chen, HJ Cordell, SP Davies, GL Gupte, Gideon Morris Hirschfield, Rebecca Jeyaraj, DE Jones et al. · 2025 · medRxiv
Future Treatment Options for Managing Primary Sclerosing Cholangitis and Cholestatic Pruritus
Taranika Sarkar Das, Raj Vuppalanchi · 2025 · Clinics in Liver Disease
Additional file 2 of Mesenchymal stem cell-derived exosomal miR-27b-3p alleviates liver fibrosis via downregulating YAP/LOXL2 pathway
Cheng, Fang, Yang, Fuji, Wang, Yanjin, Jing Zhou, Qian, Hui, Yan, Yongmin · 2023 · Figshare
Additional file 3 of Mesenchymal stem cell-derived exosomal miR-27b-3p alleviates liver fibrosis via downregulating YAP/LOXL2 pathway
Cheng, Fang, Yang, Fuji, Wang, Yanjin, Zhou, Jing, Qian, Hui, Yan, Yongmin · 2023 · Figshare
Additional file 1 of Mesenchymal stem cell-derived exosomal miR-27b-3p alleviates liver fibrosis via downregulating YAP/LOXL2 pathway
Cheng, Fang, Yang, Fuji, Wang, Yanjin, Jing Zhou, Qian, Hui, Yan, Yongmin · 2023 · Figshare
Additional file 4 of Mesenchymal stem cell-derived exosomal miR-27b-3p alleviates liver fibrosis via downregulating YAP/LOXL2 pathway
Cheng, Fang, Yang, Fuji, Wang, Yanjin, Jing Zhou, Qian, Hui, Yan, Yongmin · 2023 · Figshare
Pediatric cirrhosis: special consideration for its diagnosis and management
Guillermo Alejandro Costaguta, Fernando Álvarez · 2025 · Exploration of Digestive Diseases
Update on Biomarkers in Primary Sclerosing Cholangitis
Mariko Maxwell, David N. Assis · 2026 · Current Hepatology Reports
Liver pathophysiology at the single cell level : characterization of cellular heterogeneity and identification of novel therapeutic targets for chronic liver diseases and hepatocellular carcinoma
Antonio Saviano · 2019 · theses.fr (ABES)
L'activité kinase de FAK dans les fibroblastes associés au cancer : régulateur clé de la progression de l'adénocarcinome pancréatique canalaire
Sonia Zaghdoudi · 2019 · theses.fr (ABES)
The functional role of Claudin-1 as a mediator and therapeutic target in liver fibrogenesis and hepatocarcinogenesis
Natascha Roehlen · 2021 · theses.fr (ABES)
Rôle de l'enzyme LOXL2 dans le comportement pro-invasif des cellules de mélanome et le remodelage matriciel du stroma tumoral
Alexandrine Carminati · 2023 · theses.fr (ABES)
LOXL4: a key regulatory factor at the intersection of fibrosis and tumor progression
Yan Tian, Qingrong Li · 2026 · Human Cell
Zirconium-89 Labeling and Preliminary Evaluation of Simtuzumab as a Candidate Positron Emission Tomography (PET) Imaging Agent for Human Lysyl Oxidase-like 2 (LOXL2) in the Extracellular Matrix of Solid Tumors
Graham Ragland, Atchimnaidu Siriki, Kaustab Ghosh, Sarah Thau, Lucas Gonzalez, Nicholas Feinberg, Satish K. Chitneni · 2026 · ACS Pharmacology & Translational Science
CCL24 Blockade with Nebokitug Modulates Inflammation and Fibrosis Signatures in Primary Sclerosing Cholangitis
Revital Aricha, Tom Snir, John Lawler, Adi Mor · 2026 · Cells
Drug repurposing in fibrosis: From molecular networks to antifibrotic therapeutics—A narrative review
Raihana Nilofar A, Krishnasai Sathiamoorthy, Prabakaran Karthick Rajan, Priyadharsini Rajendran · 2026 · British Journal of Clinical Pharmacology
BindingDB Entry 50007641: The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
BindingDB · 2021 · UC San Diego